When was Ironfist Therapeutics founded?

Ironfist Therapeutics was founded in 2025.

Where is Ironfist Therapeutics located?

Ironfist Therapeutics is headquartered in Redwood City, United States.

Who is the current CEO of Ironfist Therapeutics?

Jeffrey Cleland of Ironfist Therapeutics. They have also founded 1 company.

Where does Ironfist Therapeutics rank among its competitors?

Ironfist Therapeutics ranks 1806th amongst 2519 active competitors, of which 863 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Ironfist Therapeutics?

Ironfist Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Ironfist Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of radiopharmaceuticals targeting tumor associated macrophages for cancer treatment. These therapeutic agents utilize targeted delivery systems to transport radioisotopes directly to immunosuppressive cells within the tumor microenvironment. By eliminating these specific macrophages, the therapy aims to restore immune system recognition and facilitate an anti-tumor response. The platform supports the development of various radiopharmaceutical products designed for solid tumors that demonstrate resistance to conventional immunotherapies.

Key Metrics

Founded Year

2025

Location

Redwood City, United States

Stage

Funding Raised

Investors

Tribe Capital

Ranked

1806^th among 2519 active competitors

Similar Companies

Molecular Partners & 101 more

View Ironfist Therapeutics' full profile

Ironfist Therapeutics is a funded company. Ironfist Therapeutics has 1 institutional investor.

View details of Ironfist Therapeutics's funding rounds and investors

The founders of Ironfist Therapeutics are Jay Zaveri, Jeffrey Cleland, Kannan R Rangaramanujam, Arjun Sethi and Sujatha Kannan. Jeffrey Cleland is the CEO of Ironfist Therapeutics.

Here are the details of Ironfist Therapeutics' key team members:

Jay Zaveri: Co-Founder of Ironfist Therapeutics. They are also an angel investor in 1 startup and serve on the board of 1 company.
Jeffrey Cleland: Co-Founder & CEO of Ironfist Therapeutics and founder of 1 other company.
Kannan R Rangaramanujam: Co-Founder of Ironfist Therapeutics.
Arjun Sethi: Co-Founder of Ironfist Therapeutics.
Sujatha Kannan: Co-Founder of Ironfist Therapeutics.

View details of Ironfist Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ironfist Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Ironfist Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
1806th	Ironfist Therapeutics 2025, Redwood City (United States), Funding Raised	Developer of radiopharmaceuticals targeting tumor associated macrophages for cancer treatment	-	Tribe Capital	25/100